Kymera Therapeutics Inc

Kymera Therapeutics CEO Nello Mainolfi’s March 2026 stock‑option grant shows a mix of liquidity needs and long‑term confidence, while raising dilution concerns for investors.

Kymera Therapeutics insider sale: Booth Bruce’s structured 71k‑share trade at $90.13 shows cautious liquidity amid clinical milestones and market volatility.

Kymera Therapeutics CEO Nello Mainolfi buys 30k shares at $2.08 while selling higher, signaling confidence in the degrader platform and a bullish outlook for the protein‑degradation company.

Kymera Therapeutics insider buys 2,500 shares at $49.10, 14% below market – a bullish sign ahead of new clinical data or partnership news.